SEC Form 4 · accession 0001676170-26-000020
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason V Coloma
Officer — Chief Executive Officer · Director
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001842295
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 1, 2026 | S | 2,593 | $26.307 | D | 18,151 | I | The Coloma 2021 Irrevocable Trust |
| Common StockF4,F5 | Sep 1, 2026 | S | 31,908 | $26.2876 | D | 223,355 | I | Coloma Family Trust |
| Common Stock | Sep 1, 2026 | M | 50,000 | $0.00 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF6,F7,F8 | — | Sep 1, 2026 | M | 50,000 | D | — | — | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.50 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.
- F3These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.13 to $26.555 per share, inclusive.
- F5These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.
- F6Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- F7The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
- F8These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.